Skip to main content

ADVERTISEMENT

vemurafenib

Research in Review
01/26/2017
JCP Editors
The addition of BRAF-inhibitor vemurafenib to irinotecan and cetuximab chemotherapy treatment improves progression-free survival (PFS) for patients with BRAF-mutant metastatic colorectal cancer, according to a...
The addition of BRAF-inhibitor vemurafenib to irinotecan and cetuximab chemotherapy treatment improves progression-free survival (PFS) for patients with BRAF-mutant metastatic colorectal cancer, according to a...
The...
01/26/2017
Journal of Clinical Pathways